Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG2025 Monotherapy and with Nivolumab in Solid Tumors
NCT05266612Phase 1Recruiting
- Sponsor
- Virogin Biotech
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of VG2025 in advanced malignant solid tumor (2 arms), sponsored by Virogin Biotech. Primary endpoints: Incidence of Adverse Events at 12 months and Maximum Tolerated Dose at 12 months. Started Nov 2022; status: recruiting.
02
Drugs
VG2025
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05266612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266612.